Pfizer has previously announced that it would stop marketing Exubera inhalation powder because it did not meet customers’ needs or Pfizer’s financial expectations. Since that time, Exubera patients have been transitioning to other diabetes therapies, although there remains a small number of patients with a continuing medical need for inhaled insulin.
Pfizer began discussions with MannKind to give these patients access to Technosphere Insulin. Pfizer will reimburse some of MannKind’s costs relating to the transition of patients.
Hakan Edstrom, president and COO of MannKind, said: “We’re pleased to work with Pfizer as we transition these patients and to help them manage their diabetes.”